The impact of the use of antiepileptic drugs on the growth of children

BMC Pediatrics

Hueng-Chuen Fan³  Shyi-Jou Chen³  Chih-Chien Wang¹  Donald M Salter²  Shih-Yu Wang⁴  Herng-Sheng Lee⁴ 

[1] Department of Orthopaedics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan;Center for Molecular Medicine, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, UK;Department of Paediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan;Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

关键词: Lamotrigine;    Topiramate;    Oxcarbazepine;    Valproic acid;    Antiepileptic drugs;   

Others  :  1144033
DOI  :  10.1186/1471-2431-13-211

 received in 2013-02-08, accepted in 2013-12-14,  发布年份 2013

【 摘 要 】

Background

This study investigated whether long-term treatment with antiepileptic drugs (AEDs) had negative effects on statural growth and serum calcium levels in children with epilepsy in Taiwan.

Methods

Children with epilepsy treated with one prescription of AEDs (monotherapy) for at least 1 year were selected. The AEDs included valproic acid (VPA; Deparkin) in 27 children (11 boys and 16 girls) aged 4-18 years, oxcarbazepine (Trileptal) in 30 children (15 boys and 15 girls) aged 5-18 years, topiramate (Topamax) in 19 children (10 boys and 9 girls) aged 6-18 years, and lamotrigine (Lamicta) in eight children (5 boys and 3 girls) aged 5-13 years. Patients with a history of febrile convulsions were selected as the controls.

Results

One year of VPA treatment significantly impaired the statural growth of pediatric patients with epilepsy (p < 0.005) compared with the control group. The underlying mechanism may have been due to the direct effect of VPA on the proliferation of growth plate chondrocytes rather than alterations of serum calcium.

Conclusions

These results raise serious concerns about the growth of pediatric epilepsy patients who use AEDs, and potentially the need to closely monitor growth in children with epilepsy and adolescents under AED treatment, especially VPA.

【 授权许可】

   
2013 Lee et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ripamonti U, Roden L: Biomimetics for the induction of bone formation. Expert Rev Med Devices 2010, 7:469-479.
• [2]van der Eerden BC, Karperien M, Wit JM: Systemic and local regulation of the growth plate. Endocr Rev 2003, 24:782-801.
• [3]Rauch F: Bone growth in length and width: the Yin and Yang of bone stability. J Musculoskelet Neuronal Interact 2005, 5:194-201.
• [4]Qin C, Baba O, Butler WT: Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 2004, 15:126-136.
• [5]Rodriguez L, Cheng Z, Chen TH, Tu C, Chang W: Extracellular calcium and parathyroid hormone-related peptide signaling modulate the pace of growth plate chondrocyte differentiation. Endocrinology 2005, 146:4597-4608.
• [6]Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, Engel J Jr: Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
• [7]Chen CC, Chen TF, Hwang YC, Wen YR, Chiu YH, Wu CY, Chen RC, Chen TH, Liou HH: Population-based survey on prevalence of adult patients with epilepsy in Taiwan (Keelung community-based integrated screening no. 12). Epilepsy Res 2006, 72:67-74.
• [8]Greenwood RS: Adverse effects of antiepileptic drugs. Epilepsia 2000, 41(Suppl 2):S42-S52.
• [9]Pack AM, Gidal B, Vazquez B: Bone disease associated with antiepileptic drugs. Cleve Clin J Med 2004, 71(Suppl 2):S42-S48.
• [10]Sheth RD: Metabolic concerns associated with antiepileptic medications. Neurology 2004, 63:S24-S29.
• [11]Valmadrid C, Voorhees C, Litt B, Schneyer CR: Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001, 58:1369-1374.
• [12]Morijiri Y, Sato T: Factors causing rickets in institutionalised handicapped children on anticonvulsant therapy. Arch Dis Child 1981, 56:446-449.
• [13]Vestergaard P: Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand 2005, 112:277-286.
• [14]Robinson PB, Harris M, Harvey W: Abnormal skeletal and dental growth in epileptic children. Br Dent J 1983, 154:9-13.
• [15]Guo CY, Ronen GM, Atkinson SA: Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 2001, 42:1141-1147.
• [16]Pack A: Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008, 17:181-186.
• [17]Samaniego EA, Sheth RD: Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol 2007, 14:196-200.
• [18]Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC: Use of antiepileptic drugs and risk of fractures: case–control study among patients with epilepsy. Neurology 2006, 66:1318-1324.
• [19]Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia 2010, 51:676-685.
• [20]Luna-Tortos C, Fedrowitz M, Loscher W: Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 2010, 58:1019-1032.
• [21]Brochhausen C, Neuland P, Kirkpatrick CJ, Nusing RM, Klaus G: Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ–prostaglandin E2 dependent proliferation of growth plate chondrocytes. Arthritis Res Ther 2006, 8:R78. BioMed Central Full Text
• [22]Lee HS, Lee CH, Tsai HC, Salter DM: Inhibition of cyclooxygenase 2 expression by diallyl sulfide on joint inflammation induced by urate crystal and IL-1beta. Osteoarthritis Cartilage 2009, 17:91-99.
• [23]Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, Bodensteiner JB: Effect of carbamazepine and valproate on bone mineral density. J Pediatr 1995, 127:256-262.
• [24]Kafali G, Erselcan T, Tanzer F: Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr (Phila) 1999, 38:93-98.
• [25]Pack AM: The association between antiepileptic drugs and bone disease. Epilepsy Curr 2003, 3:91-95.
• [26]Ali II, Schuh L, Barkley GL, Gates JR: Antiepileptic drugs and reduced bone mineral density. Epilepsy Behav 2004, 5:296-300.
• [27]Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, Spain W: Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002, 59:781-786.
• [28]Valimaki MJ, Tiihonen M, Laitinen K, Tahtela R, Karkkainen M, Lamberg-Allardt C, Makela P, Tunninen R: Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res 1994, 9:631-637.
• [29]Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB: Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 1984, 58:1003-1009.
• [30]Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT: In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001, 52:547-553.
• [31]Jette N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD: Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 2011, 68:107-112.
• [32]Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F: Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 2010, 112:1-10.
• [33]Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K: Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001, 57:445-449.
• [34]Pack AM, Morrell MJ, Marcus R, Holloway L, Flaster E, Done S, Randall A, Seale C, Shane E: Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005, 57:252-257.
• [35]Erbayat AE, Serdaroglu A, Tumer L, Gucuyener K, Hasanoglu A: Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid. J Pediatr Endocrinol Metab 2000, 13:933-939.
• [36]Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N: A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 1986, 59:569-577.
• [37]Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L: Fracture risk is increased in epilepsy. Acta Neurol Scand 1999, 99:269-275.
• [38]Mintzer S, Boppana P, Toguri J, DeSantis A: Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006, 47:510-515.
• [39]Mirza N, Marson AG, Pirmohamed M: Effect of topiramate on acid–base balance: extent, mechanism and effects. Br J Clin Pharmacol 2009, 68:655-661.
• [40]Heo K, Rhee Y, Lee HW, Lee SA, Shin DJ, Kim WJ, Song HK, Song K, Lee BI: The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia 2011, 52:1884-1889.
• [41]Khanna S, Pillai KK, Vohora D: Insights into liaison between antiepileptic drugs and bone. Drug Discov Today 2009, 14:428-435.
• [42]Kim SH, Lee JW, Choi KG, Chung HW, Lee HW: A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 2007, 10:291-295.
• [43]Sheth RD, Hermann BP: Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol 2007, 37:250-254.
• [44]Zhang CL, McKinsey TA, Olson EN: Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol 2002, 22:7302-7312.
• [45]Vallo S, Xi W, Hudak L, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA: HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anticancer Drugs 2011, 22:1002-1009.
• [46]Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM: Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004, 89:1358-1367.